[Importance of FDG-PET/CT for Surgery of Rectal Cancer]

Overview

Journal Chirurg

Specialty General Surgery

Date 2014 Mar 26

PMID 24663346

Authors

A Wiegering

K Herrmann

C Bluemel

A K Buck

C-T Germer

Affiliations

Soon will be listed here.

Abstract

Background: Examinations using 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) are becoming increasingly more important in clinical practice for the diagnosis and therapy of cancer patients.

Question: What role does FDG-PET/CT examination play in the diagnosis and therapy of rectal cancer?

Results: The FDG-PET/CT method is especially valuable during postoperative care when a recurrence is suspected. Especially when tumor marker levels rise with no other symptoms, FDG-PET/CT can be used to evaluate unclear lesions in the liver and unclear tissue formations at the surgery site and distinguish between scar tissue and recurring tumors. Currently, there is increasing evidence that a survival prognosis may be possible based on the tracer uptake of FDG-PET/CT. There is also a great interest in the possibility of evaluating the success of neoadjuvant therapy with FDG-PET/CT.

Discussion: Despite some limitations FDG-PET/CT plays a significant role in the diagnosis and treatment of patients with rectal cancer.

References

Fletcher J, Djulbegovic B, Soares H, Siegel B, Lowe V, Lyman G . Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008; 49(3):480-508. DOI: 10.2967/jnumed.107.047787. View

Bassi M, Turri L, Sacchetti G, Loi G, Cannillo B, La Mattina P . FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys. 2007; 70(5):1423-6. DOI: 10.1016/j.ijrobp.2007.08.043. View

Even-Sapir E, Parag Y, Lerman H, Gutman M, Levine C, Rabau M . Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology. 2004; 232(3):815-22. DOI: 10.1148/radiol.2323031065. View

Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R . [Update S3-guideline "colorectal cancer" 2008]. Z Gastroenterol. 2008; 46(8):799-840. DOI: 10.1055/s-2008-1027726. View

Gearhart S, Frassica D, Rosen R, Choti M, Schulick R, Wahl R . Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol. 2006; 13(3):397-404. DOI: 10.1245/ASO.2006.04.042. View

Kim J, Kim H, Park J, Park S, Sohn D, Choi H . Predictive value of (18)FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy. Int J Colorectal Dis. 2013; 28(9):1217-24. DOI: 10.1007/s00384-013-1657-1. View

Flamen P, Hoekstra O, Homans F, Van Cutsem E, Maes A, Stroobants S . Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer. 2001; 37(7):862-9. DOI: 10.1016/s0959-8049(01)00049-1. View

Zhang C, Tong J, Sun X, Liu J, Wang Y, Huang G . 18F-FDG-PET evaluation of treatment response to neo-adjuvant therapy in patients with locally advanced rectal cancer: a meta-analysis. Int J Cancer. 2012; 131(11):2604-11. DOI: 10.1002/ijc.27557. View

Heriot A, Hicks R, Drummond E, Keck J, MacKay J, Chen F . Does positron emission tomography change management in primary rectal cancer? A prospective assessment. Dis Colon Rectum. 2004; 47(4):451-8. DOI: 10.1007/s10350-003-0089-3. View

10.

Berger K, Nicholson S, Dehdashti F, Siegel B . FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol. 2000; 174(4):1005-8. DOI: 10.2214/ajr.174.4.1741005. View

11.

Davey K, Heriot A, Mackay J, Drummond E, Hogg A, Ngan S . The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer. Dis Colon Rectum. 2008; 51(7):997-1003. DOI: 10.1007/s10350-008-9244-1. View

12.

Scott A, Gunawardana D, Kelley B, Stuckey J, Byrne A, Ramshaw J . PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med. 2008; 49(9):1451-7. DOI: 10.2967/jnumed.108.051615. View

13.

Calvo F, Sole C, De la Mata D, Cabezon L, Gomez-Espi M, Alvarez E . ¹⁸F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: a prospective validation of long-term outcomes. Eur J Nucl Med Mol Imaging. 2013; 40(5):657-67. DOI: 10.1007/s00259-013-2341-y. View

14.

Sobhani I, Tiret E, Lebtahi R, Aparicio T, Itti E, Montravers F . Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer. 2008; 98(5):875-80. PMC: 2266857. DOI: 10.1038/sj.bjc.6604263. View

15.

Ruers T, Wiering B, van der Sijp J, Roumen R, de Jong K, Comans E . Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med. 2009; 50(7):1036-41. DOI: 10.2967/jnumed.109.063040. View

16.

Shen Y, Liang J, Chen Y, Tsai C, Kao C . Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan. Hepatogastroenterology. 2006; 53(69):348-50. View

17.

Vriens D, de Geus-Oei L, van der Graaf W, Oyen W . Tailoring therapy in colorectal cancer by PET-CT. Q J Nucl Med Mol Imaging. 2009; 53(2):224-44. View

18.

Lu Y, Chen J, Chien C, Chen W, Tsai S, Lin W . Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis. Int J Colorectal Dis. 2013; 28(8):1039-47. DOI: 10.1007/s00384-013-1659-z. View

19.

Kamel E, Thumshirn M, Truninger K, Schiesser M, Fried M, Padberg B . Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med. 2004; 45(11):1804-10. View

20.

Muthusamy V, Chang K . Optimal methods for staging rectal cancer. Clin Cancer Res. 2007; 13(22 Pt 2):6877s-84s. DOI: 10.1158/1078-0432.CCR-07-1137. View